Imagine your vision slowly blurring and your eye swelling after cataract surgery. That's the reality of Irvine-Gass syndrome (IGS), a frustrating complication that can steal a person's clear sight. A new review of past patient records looked at whether injections of a drug called anti-VEGF directly into the eye could help. The review pooled data from 334 patients (343 eyes) who received these injections. After about six months, on average, patients' vision improved and the swelling in the center of their eye decreased. In the few studies that tracked it, the fluid buildup causing the problem resolved in a majority of eyes. This is encouraging news for a condition with limited treatment options. However, it's important to understand what this review can and cannot tell us. The main finding comes with significant caution. The studies were mostly retrospective, meaning researchers looked back at old medical charts rather than designing a controlled experiment. The way different studies reported their main results was too messy to combine for a stronger analysis. Most importantly, we still don't know if these injections work better than a simple placebo injection, because only one small study made that direct comparison. The review suggests potential benefit, but it's a signal calling for better, more definitive research.
Can eye injections help people with Irvine-Gass syndrome see better?
Photo by Dmytro Vynohradov / Unsplash
What this means for you:
Eye injections show promise for Irvine-Gass syndrome, but stronger studies are needed to prove they work best. More on Cystoid Macular Edema
Meta-analysis: Anti-VEGF biosimilars show equivalent efficacy, safety to reference agents in nAMD Can cheaper eye drugs work as well as expensive ones? A major review says yes for vision loss in older adults
· Mar 30, 2026
Review of ovarian cancer treatments including olaparib, bevacizumab, and durvalumab discusses limitations and biomarkers New drug combos target hidden cancer switches to stop resistance
Frontiers · May 1, 2026
Aflibercept 8 mg extended dosing maintains visual gains with fewer injections versus 2 mg every 8 weeks in DME Aflibercept 8 mg every 16 weeks matches standard dosing for diabetic macular edema
· May 1, 2026
Systematic review and meta-analysis shows aflibercept biosimilars match reference drug efficacy and safety in AMD and DME Aflibercept biosimilars match the original drug for eye disease treatment
· May 1, 2026